CDSCO clears recombinant live attenuated dengue vaccine for ages 4 to 60 years
India's Central Drugs Standard Control Organisation has approved the Qdenga dengue vaccine for individuals aged 4 to 60. Developed by Takeda, the vaccine uses recombinant DNA technology and has already received regulatory approval in 42 other countries.
Why it matters
The approval of the first dengue vaccine in India marks a major milestone in public health efforts to combat a widespread, endemic mosquito-borne disease.
India has approved its first dengue vaccine , with the Central Drugs Standard Control Organisation (CDSCO) granting marketing authorisation for the Dengue Tetravalent Vaccine (Live, Attenuated) – Qdenga. Manufactured by Takeda GmbH, Germany, the vaccine will be imported by Takeda Biopharmaceuticals India Pvt. Ltd.
The vaccine is indicated for the prevention of dengue in individuals 4 to 60 years of age.
“The approval has been granted after a comprehensive scientific evaluation of the vaccine’s quality, safety and efficacy in accordance with the provisions of the Drugs and Cosmetics Act, 1940 and the Drugs Rules, 1945,” said a statement issued by the Union Health Ministry on Tuesday (July 21, 2026).
Qdenga is a live, attenuated tetravalent dengue vaccine developed using recombinant DNA technology. The vaccine is produced in Vero cells, with genes encoding serotype-specific surface proteins engineered into a dengue virus type-2 backbone.
The product contains genetically modified organisms (GMOs).
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in